Reviva Pharmaceuticals' CEO will present at the Neuroscience Innovation Forum on January 11, 2026, discussing their drug candidates.
Quiver AI Summary
Reviva Pharmaceuticals Holdings, Inc., a late-stage biopharmaceutical company focused on developing therapies for central nervous system, inflammatory, and cardiometabolic diseases, announced that CEO Dr. Laxminarayan Bhat will present at the Sachs 9th Annual Neuroscience Innovation Forum on January 11, 2026, in San Francisco. The presentation will highlight Reviva's leading projects, including their drug candidates brilaroxazine (RP5063) and RP1208, both of which are novel compounds with patent protections in multiple regions. The company aims to address significant unmet medical needs and challenges faced by patients and society.
Potential Positives
- Reviva Pharmaceuticals is scheduled to present at a significant industry event, the Sachs 9th Annual Neuroscience Innovation Forum, which can enhance its visibility and attract interest in its pipeline.
- The company has a focus on addressing unmet medical needs in vital therapeutic areas such as CNS, inflammatory, and cardiometabolic diseases, showcasing its commitment to meaningful healthcare advancements.
- Reviva's pipeline includes two drug candidates, brilaroxazine (RP5063) and RP1208, both of which are new chemical entities, indicating ongoing innovation and research within the company.
- Reviva has secured composition of matter patents for its drug candidates in multiple regions, which can provide a competitive edge and potential for commercial success.
Potential Negatives
- Company's emphasis on being a late-stage biopharmaceutical firm may indicate a longer timeline to profitability and market success, which may concern investors looking for quicker returns.
- The press release provides limited information on the current status or progress of their drug candidates, which could lead to uncertainty about their development and potential impact.
- There is no mention of recent financial performance or funding status, raising questions about the company's financial health and ability to sustain its operations going forward.
FAQ
What is Reviva Pharmaceuticals focused on?
Reviva Pharmaceuticals focuses on developing therapies for central nervous system, inflammatory, and cardiometabolic diseases.
When will Reviva's CEO present at the Neuroscience Innovation Forum?
Laxminarayan Bhat, Ph.D., will present on January 11, 2026, at 1:20 PM PT.
Where is the Neuroscience Innovation Forum taking place?
The forum will be held at the Marines’ Memorial Club in San Francisco, CA.
What drug candidates are in Reviva's pipeline?
Reviva’s pipeline includes two candidates: brilaroxazine (RP5063) and RP1208, both discovered in-house.
What patents has Reviva been granted for its drug candidates?
Reviva has received composition of matter patents for brilaroxazine and RP1208 in the U.S., Europe, and other countries.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
Full Release
CUPERTINO, Calif., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the Sachs 9 th Annual Neuroscience Innovation Forum, taking place January 11, 2026, in San Francisco, CA.
Presentation Details:
Format:
Corporate Presentation
Date:
Sunday, January 11, 2026
Time:
1:20 PM PT
Presenter:
Laxminarayan Bhat, Ph.D., Reviva Pharmaceuticals
Location:
Marines’ Memorial Club, San Francisco, CA
About Reviva
Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva’s current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva’s pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.
Corporate Contact:
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD
www.revivapharma.com
Investor Relations Contact:
LifeSci Advisors, LLC
PJ Kelleher
[email protected]
